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In this study, we investigated whether fluorescein
isothiocyanate (FITC)-labeling of test DNA and Texas-
red (TR) labeling of reference DNA in comparative
genomic hybridization (CGH) experiments cause the
results to differ from those obtained using the oppo-
site combination (reverse labeling). Analysis was
performed on a total of 20 DNA specimens consist-
ing of 13 frozen bone marrow aspirates from pa-
tients with acute myeloid leukemia, and fresh periph-
eral blood samples from seven healthy donors. For
CGH, one aliquot from each test DNA sample was
labeled using nick-translation with FITC-dUTP and
another with TR-dUTP. Afterwards, the FITC-dUTP
and TR-dUTP-labeled test DNAs were hybridized to
TR-dUTP- and FITC-dUTP-labeled normal reference
DNAs, respectively. The results using the two combi-
nations were compared with each other and with
the results of G-banding karyotype analysis. Karyo-
type data was used to detect artifacts known to occur
in some chromosome regions in CGH analysis. The
control DNAs labeled with FITC or TR showed no
DNA copy number changes. Regardless of the fluoro-
chrome employed for labeling, no DNA copy num-
ber changes were detected using CGH in patients
with normal karyotypes, nor in patients whose
karyotype aberrations were present in less than 40%
of cells. In the remaining patients, CGH revealed
DNA copy number changes that coincided with the
results of the G-banding analysis. Hybridization arti-
facts known to occur in CGH experiments affecting
chromosome regions 1p33-pter, 16p, 17p, 19, and 22
were observed in 15–23% of the tumor samples
labeled with FITC, but not in samples labeled with
TR. In addition, other previously unreported overrep-
resentations affecting 7q21, 9q34, 16q, 17q, and
chromosome 20 were observed at very low frequen-
cies in up to 10% of the samples when FITC was used
to label test DNA. However, when TR was used,
overrepresentations were observed at 4q13–q21,
11q21–q23, 13q21-qter, and Xq21–q22, whereas 19p
was underrepresented. The results demonstrate that
TR-labeling confirms abnormalities detected using
FITC-labeling and reduces hybridization artifacts in
the known problematic regions of the human ge-
nome. Cytometry 31:174–179, 1998.
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Since the development of the comparative genomic
hybridization (CGH) methodology presented by Kallioni-
emi and collaborators in 1992 (6), the procedure has been
beset with technical limitations and difficulties. Among
them, DNA copy number changes in 1p, 16p, 17p, and in
the whole of chromosomes 19 and 22 are considered
difficult to interpret, leading to false-positive observations
(7,8,18). It has been suggested that this drawback can be
overcome by using fluorochrome-conjugated nucleotides
during the nick translation procedure (direct method), i.e.,
labeling with fluorescein isothiocyanate (FITC) or Texas-
red (TR)(7,18). In addition, a very uniform hybridization is
achieved with nucleotide-conjugated fluorochromes, which
Contract grant sponsor: Helsinki University Central Hospital; Contract
grant sponsor: Sigrid Juse´lius Foundation; Contract grant sponsor: Finnish
Cancer Society in Finland; Contract grant sponsor: National Council of
Scientific and Technological Research (CONICET); Contract grant spon-
sor: National University of La Plata in Argentina.
*Correspondence to: Sakari Knuutila, Laboratory of Medical Genetics,
Helsinki University Central Hospital, P.O. Box 404, Haartmaninkatu 3,
FIN-00029 HUCH, Helsinki, Finland.
E-mail: sknuutil@cc.helsinki.fi
r 1998 Wiley-Liss, Inc. Cytometry 31:174–179 (1998)
favors the interpretation and resolution of the ratio pro-
files. Accordingly, the direct method for visualizing hybrid-
ized DNAs in CGH protocols has been adopted in many
recent studies (2–5,9,10,13,14,18,19). Interchanging the
labels between the test and reference DNAs (reverse
labeling) has been suggested as a method to confirm CGH
results obtained using FITC (7,13,16-18).
In this study, we investigated whether FITC-labeling for
test DNA and TR-labeling for reference DNA in CGH
experiments cause the results to differ from those ob-
tained using reverse labeling. A total of 20 samples (bone
marrow from 13 patients with acute myeloid leukemia
(AML) or peripheral blood from seven normal donors)
were analyzed using both combinations and the results
were compared with each other and with those obtained
from conventional karyotype analysis. The karyotypic data
were used to clarify the unresolved issue of hybridization
artifacts encountered in specific regions of the human
genome.
MATERIALS AND METHODS
DNA Specimens
The material consisted of frozen bone marrow aspirates
from 13 patients with AML obtained from the Department
of Medicine (Helsinki University Central Hospital, Hel-
sinki). In addition, samples of peripheral blood from seven
normal donors (controls) were included in the study. DNA
was extracted using standard procedures.
Conventional Cytogenetic Analysis
Bone marrow aspirates from the AML patients and
peripheral blood samples from the controls were studied
using standard G-banding methods (11).
Comparative Genomic Hybridization
Comparative genomic hybridization (CGH) was per-
formed using direct fluorochrome-conjugated DNAs for all
samples according to a recently published protocol with
minor modifications (7). Briefly, the tumor, control and
reference DNAs were labeled by nick translation with
FITC-dUTP (DuPont, Boston, MA) and TR-dUTP (DuPont)
to obtain DNA fragments of 600–2,000 base pairs (bp).
Each DNA sample was divided in two aliquots: one labeled
with FITC-dUTP and the other with TR-dUTP. The hybrid-
ization mixture consisted of 400 ng of labeled tumor or
control DNA, 400 ng of differently labeled reference DNA,
and 10 µg of unlabeled human Cot-1 DNA (Gibco-BRL, Life
Technologies, Gaithersburg, MD) dissolved in 10 µl of
hybridization buffer (50% formamide, 10% dextran sulfate,
23 SSC). The mixture was denatured at 75°C for 5 min,
then hybridized onto normal metaphases denatured in
70% formamide/23 SSC (65°C, 2 min). Hybridization was
carried out at 37°C for 48 h. The slides were then washed
three times in 50% formamide/23 SSC (pH 7.0), twice in
23 SSC and once in 0.13 SSC (45°C, 10 min each),
followed by washes in 23 SSC, in a buffer containing 0.1 M
NaH2PO4 and 0.1M Na2HPO4 (pH 8.0), and in distilled
water (room temperature, 10 min each). The slides were
counterstained with 48,6-diamidino-2-phenylindole-dihydro-
chloride (DAPI) and mounted with Vectashieldt antifad-
ing buffer (Vector Laboratories, Burlingame, CA).
Nick-translation, precipitation, hybridization, and wash-
ings were carried out simultaneously for each pair of FITC-
and TR-labeled DNA samples from the same specimen, to
minimize intra-experiment variation.
Digital Image Analysis
The hybridizations were analyzed using an Olympus
fluorescence microscope and the ISIS digital image analy-
sis system (MetaSystems GmbH, Altlussheim, Germany),
which comprises an integrated high-sensitivity mono-
chrome CCD camera and automated CGH analysis soft-
ware. Three-color images, green (FITC), red (TR) and blue
(DAPI for the chromosome counterstaining) were ob-
tained from 12-20 metaphases in each hybridization.
Chromosome regions were interpreted as overrepre-
sented if the corresponding color ratio was higher than
1.17 (gains) or 1.5 (high-level amplifications), and under-
represented if the ratio was lower than 0.85 (losses).
These cutoff values were derived from analyses of negative
controls whereby two differently labeled normal DNAs
were hybridized against each other.
All results were confirmed within a 99% confidence
interval. Briefly, intra-experimental standard deviations for
all positions of the CGH ratio profile were calculated from
the variation of the ratio values of all homologous chromo-
somes within the experiment. Confidence intervals for the
ratio profiles were then computed by combining them
with an empirical inter-experiment standard deviation and
estimating the error probabilities based on the t-distribu-
tion.
RESULTS
G-banding analysis revealed that all our controls had
normal karyotypes and that 11 out of 13 AML patients had
various karyotypic aberrations (Table 1). CGH did not
reveal any DNA copy number changes in the control
samples (donors 14-20) labeled with FITC or TR (Table 1)
using cutoff values of 0.85 for losses and 1.17 for gains
(Table 1).
Eleven tumor samples (donors 1, 2, 4-8, and 10–13)
showed complex chromosomal aberrations in the banding
analysis, and DNA copy number changes were detected by
CGH using both labeling systems in all but one of the
samples (donor 11) (Table 1). Chromosomal regions with
an increase or decrease in the DNA sequence copy
number are summarized in Figure 1. Changes in DNA copy
number were not observed in one patient whose karyo-
type was normal (donor 9), nor in one patient (donor 11)
who had chromosomal imbalances present in 33% of the
metaphases from which the karyotype was determined.
For some patients (donors 4, and 6–8), the karyotype
analysis revealed marker chromosomes and monosomies
of chromosomes 2, 4, 5, 6, 7, 12, 16, 17, 20, and 22. In the
CGH analysis, some of these chromosomes were either
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normal or had only partial deletions, suggesting a rearrange-
ment of the remaining DNA material in the marker
chromosomes. In one patient (donor 10), CGH did not
reveal the del(9)(q34) found in 31% of cells studied for
karyotype analysis. However, CGH revealed some DNA
copy number changes that were not observed in G-banding
analysis (donors 2–5, 7–10, 12, and 13) (Table 1, Figure 1).
Moreover, some DNA copy number losses, which did not
match any chromosomal aberrations seen in the G-banding
analysis, were observed in donors 4 and 7 (Table 1, Fig. 1).
Figure 1 illustrates that, of the aberrations detected by
both fluorochromes, 42% of the gains or losses observed in
FITC-labeled DNA extended into a wider chromosomal
area than that revealed by TR-labeling. Overrepresentation
in 1p33-pter, 16p, 17p, 19, and 22 were observed in
15–23% of the tumor samples labeled with FITC, but not in
those labeled with TR.
Furthermore, it is evident from Figure 1 that, in addition
to those chromosomal regions reported to have false-
positive results, chromosomal imbalances not supported
Table 1
Cytogenetic Characteristics and DNA Copy Number Changes in Tumor and Control Specimens Analyzed
by Comparative Genomic Hybridization
Donor No.
(sex, age)a Code
Specimen
typeb Chromosome studyc
DNA copy number changes CGH resultsd
Losses Gains
1
(M, 23)
890581 AML 47,XY,18,t(8;12)(p21;p11),
del(12)(p11p1?3) [9]
F: 12p12
T: No
F: 8
T: 8
2
(F, 40)
890827 AML 46,XX,del(7)(q31.2) or
del(7)(q22q34),inv(16)(p13q22)
[11]/46,XX[1]
F: 7q31-qter
T: 7q31-qter
F: 17p12-q24
T: No
3
(M, 21)
900417 AML 46,XY[20] F: No
T: No
F: No
T: No
4
(M, 50)
910986 AML 43-45,XY,add(2)(p?21),i(5)(p10),
-7,18,-12,-16,-17,t(17;?)
(p11.2;?),11-3mar,inc [cp17]
F: 5q13-qter, 7, 16, 18q
T: 5q14-qter,7p15-qter, 16
F: No
T: No
5
(F, 39)
911322 AML 46,XX,del(5)(q13q33),
del(7)(q?21.1q?34),
del(12)(p11.2 or p13) [15]
F: 5q14-q3l, 7q21-q32,
12p12
T: 5q15-q31, 7cen-q31
F: 17
T: No
6
(F, 47)
920391 AML 45,XX,del(3)(q21q26),-6,7,
-22,1mar1,1mar2[12]
F: 6q16-q21, 7p, 7q22-qter
T: 6q16-q21, 7p, 7q22-qter
F: No
T: No
7
(M, 66)
940819 AML 45,XY,-5,-17,-20,12 mar,inc[3]/
42,XY,idem,-4,-5,-7,add(11)
(p11),-16,13-4 mar,
inc[7]/88,idemx2,inc[3]
F: 4p, 4q23-qter,5cen-q13,
5q21-q33, 7p12-q11.2,
7q31-qter, 12q22-qter, 16,
17
T: 4p, 4q31-qter,5q22-
q31, 7p13-q11.2, 7q32-
qter, 12q22-qter, 16, 17,
19p
F: 7q21, 8
T: 4q13-q21, 8, 11q21-q23,
13q21-qter
8
(M, 47)
950392 AML 46,XY,-2,der(3)?x2,der(5)t(1;5)
(p11;q35)del(5)(q13q35),der(7)
t(3;7)(q25;q22),i(8)(q10),11-2
mar,inc[10]
F: 3p21-pter, 3cen-q21,
5q14-q31, 7q32-qter,
8cen-p12
T: 3p21-pter, 5q21-q31,
7q32-qter, 8p
F: 1p22-pter, 2p13-p23, 8q
T: 1p31-p32, 2p15-p23, 8q,
Xq21-q22
9
(M, 50)
950979 AML 46,XY[20] F: No
T: No
F: 1p33-pter, 20,22
T: No
10
(M, 49)
870087 AML 46,XY,del(9)(q3?4)[4]/46, XY[13] F: No
T: No
F: 16p12-qter, 19
T: No
11
(M, 34)
910327 AML 45, XY,del(9)(p22),-20[6]/
46,XY[12]
F: No
T: No
F: No
T: No
12
(M, 51)
930132 AML 46,XY,t(9;12)(q34;q11),t(12;14)
(q?14;q32),inc[14]
F: No
T: No
F: 1p33-pter, 17q12-qter
22
T: 17q24-qter
13
(M, 64)
950689 AML 46,XY,del(7)(q22q36)[6]/
46,XY[10]
F: No
T: No
F: 1p33-pter, 17q12-qter,
22
T: No
14-20
(3M, 4F),
(25-43)
ND 46,XY or 46,XX F: No
T: No
F: No
T: No
aF, female; M, male; age in years at diagnosis.
bAML, acute myeloid leukemia; ND, normal donor.
cAfter G-banding analysis.
dF, FITC-labeled DNA; T, Texas red-labeled test DNA.
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by karyotyping also occur at very low frequencies in
regions not previously reported. When test-DNA was
labeled with FITC, overrepresentation of DNA copy num-
ber was seen in 7q21 (5%), 9q34 (5%), 16q (5%), and 17q
(10%) and in chromosome 20 (5%), whereas underrepre-
sentation was only observed in chromosome 18 (5%).
When TR was used for labeling of test DNA, overrepresen-
tation was observed at 4q13–q21 (5%), 11q21–q23 (5%),
13q 21-qter (5%), and Xq21–q22 (5%), but 19p (5%) was
found to be underrepresented (Fig. 1).
DISCUSSION
Our results showed that CGH did not reveal any DNA
copy number changes in control samples using either
FITC- or TR-labeling. However, artifacts known to occur in
chromosomes 1, 16, 17, 19, and 22 were observed in
15–23% of the tumor DNAs when labeled with FITC, but
not when labeled with TR. In addition, overrepresentation
at 7q21, 9q34, 16q, 17q and in chromosome 20, as well as
losses of DNA sequence copy number in chromosome 20
were observed in FITC-labeled test DNA, whereas TR-
labeled tumor DNAs showed overrepresentation at 4q13–
21, 11q21–q23, 13q21-qter, and Xq21–q22, and underrep-
resentation at 19p. Since these regions of gains and losses
were not supported by karyotyping, they are most prob-
ably artifacts caused by the use of the fluorochromes. In
agreement with our observations are previous findings
reporting discrepancies in the results depending on the
fluorochromes used to label DNA (1,21). It has to be noted
that the tumor DNA was obtained from frozen material,
FIG. 1. Summary of gains and losses in DNA sequence copy number in
13 acute myeloid leukemia samples analyzed by comparative genomic
hybridization. Losses are shown on the left side of each chromosome and
gains on the right. Single and double bars, genetic aberration seen in one
sample; solid bars, DNA copy number changes observed in FITC-labeled
DNA; empty bars, DNA copy number changes observed using Texas red;
hatched bars, karyotyping results. Figures above the bar(s) denote donor
number. All cases with marker chromosomes are indicated by X under the
corresponding bar.
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whereas the control DNA was from fresh blood samples.
Differences in the DNA preparation and/or storage there-
fore existed and could have been one factor responsible
for the hybridization artifacts seen only in the tumor
samples. It would be ideal to extract the reference DNA
and tumor DNA from tissue of the same origin and under
the same laboratory conditions. However, this may be
difficult to accomplish during routine laboratory work.
Although the precise mechanism(s) underlying labeling
and hybridization in these problematic areas of the ge-
nome are unknown, it has been suggested that the reverse
labeling system using TR could be one way to confirm the
results for those areas known to be affected by hybridiza-
tion artifacts (7,13,17,18). We found that reverse labeling
of the tumor DNA with TR essentially confirmed the CGH
results obtained using FITC-labeling, and suppressed simul-
taneously the hybridization artifacts affecting chromo-
somes 1, 16, 17, 19, and 22. Nevertheless, the analysis
showed other artifacts inherent to TR-labeling, such as
gains in up to 5% of the samples at 4q, 11q, 13q, and Xq, or
losses of DNA sequence copy number at 19p. So far, we
have no explanation for this observation. However, it
might reflect an underlying difference in the way FITC and
TR molecules bind to DNA molecules, or it could be
related to a differential affinity of the fluorochromes to
certain types of DNA families not homogeneously distrib-
uted in the genome, such as the CG rich areas or small
interspersed repeated sequence elements. It is known that
the areas reported to yield false positive results in CGH
studies correspond accurately to some of the most CG-rich
areas in the genome (20) and that some DNA molecules
are known to be highly enriched in interspersed repeated
sequences such as the SINEs, Alu family that is dominant in
reverse positive bands, and the LINEs, L1 family elements
that are dominant in Giemsa- or Quinacrine-positive bands
(12,15). Alu comprises 56% G-C and L1 is 58% A-T; each
may comprise 13–18% of the total DNA in a chromosome
band (12). Therefore, with the exception of some telo-
meric and other chromosomal regions of simple sequence
DNA, the distribution of SINEs and LINEs is precisely
inverse, suggesting an inverse functional relationship.
Comparison of the CGH data with the data obtained by
banding analysis showed that regardless of the fluoro-
chrome employed for labeling, patients with normal
karyotypes (donors 3 and 9) did not have DNA copy
number changes, nor did the patients whose karyotype
aberrations were present in less than 40% of their bone
marrow cells (donors 10, 11, and 13) nor the patient
whose sole aberrations were balanced translocations (do-
nor 12). In the remaining patients, the DNA copy number
changes revealed in CGH analysis, using both FITC- and
TR-conjugated nucleotides for labeling the tumor DNA,
coincided with the results of the G-banding analysis.
However, 42% of the gains or losses observed in FITC-
labeled DNA extended into a wider chromosomal area
than that revealed by TR-labeling. Moreover, CGH pro-
vided important information about net gains and losses of
DNA sequences in AML patients with complex karyotypes
(donors 4, 6, 7, and 8). Instead of complete monosomy,
CGH showed that the deletions are small and interstitial in
most cases, suggesting that the marker chromosomes in
these AML cases contained DNA material from the deleted
chromosomes.
In conclusion, TR-labeling of tumor DNA can be used to
confirm results obtained by FITC-labeling, especially in
samples that have DNA copy number changes in the
problematic regions of the genome. Further studies are
needed to explain the differences observed in the behavior
of these fluorochromes.
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